Oncology News | pharmaphorum

News

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in chronic lymphocytic leukaemia (CLL) that it says show a safety advantage over Imb

News

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL...

Novartis' Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences' Kite subsidiary is now looming in the rear view mirror – ar

News

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

AstraZeneca and Merck & Co's Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when

News

Bayer props up sagging radionuclide business with Noria acqu...

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofig

News

ASCO21: Novartis' prostate cancer radiotherapy extends survi...

Novartis' big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men with advanced prostate cancer and few treatment options li

News

Genmab takes aims at immuno-oncology antibody conjugates wit...

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million.

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calqu...

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL...

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

Bayer props up sagging radionuclide business with Noria acqu...

ASCO21: Novartis' prostate cancer radiotherapy extends survi...

Genmab takes aims at immuno-oncology antibody conjugates wit...

Hims & Hers to offer unapproved peptides to customers

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks